Journal of Antimicrobial Chemotherapy (2002) 49, 925-934
© 2002 The British Society for Antimicrobial Chemotherapy
Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes
Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
Received 30 July 2001; returned 11 October 2001; revised 21 December 2001; accepted 28 February 2002.
The responses of hypermutable Escherichia coli strains to selection with antibiotics having different endogenous resistance potentials were determined. Selections with rifampicin or ciprofloxacin at 4 x MIC, i.e. conditions where they act as single target agents against RpoB and GyrA, respectively, demonstrated that some hypermutators generated resistant mutants with frequencies up to 1000-fold higher than normal strains. Furthermore, individual mutants recovered from hypermutable hosts often exhibited higher levels of resistance to the drugs than mutants arising in normal hosts. Exposure to ciprofloxacin at 16 x MIC, i.e. conditions where it has low endogenous resistance potential, failed to select resistant mutants in hypermutable or normal hosts (mutation frequency <10–11). Consistent with these findings, the highest estimated mutation frequency for selection at 16 x MIC in a hypermutable host would be 4.4 x 10–15 (mutT), calculated by determining the individual mutation frequencies for first-step ciprofloxacin resistance and second-step resistance arising in hosts already harbouring single first-step mutations in gyrA at codons 83 or 87. The frequency with which second-step ciprofloxacin resistance mutations arose was suppressed in hypermutators and demonstrated at most a 10-fold increase in mutation rate compared with non-hypermutator hosts. Second-step mutants may contain mutations in mar, since a survey of 170 second-step ciprofloxacin-resistant mutants derived from both hypermutator and non-hypermutator parents demonstrated that they all possessed increased resistance to chloramphenicol, a phenotype associated with mar mutations. Exposure to 4 x MIC of D-cycloserine, cefotaxime or polymyxin B (agents with multiple targets or membrane activity) failed to select resistant mutants in normal or hypermutator hosts (mutation frequency <10–11); however, continuous culture in the presence of sub-lethal concentrations of D-cycloserine (0.25 x MIC) selected resistant mutants in hypermutators after c. 33 generations, compared with c. 44 generations in normal hosts. Since hypermutable bacteria occur naturally, our data emphasize that successful new drugs will need to possess low endogenous resistance potentials.
* Corresponding author. Tel: +44-113-233-5604; Fax: +44-113-233-5638; E-mail: I.Chopra{at}leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. F. Mandsberg, O. Ciofu, N. Kirkby, L. E. Christiansen, H. E. Poulsen, and N. Hoiby Antibiotic Resistance in Pseudomonas aeruginosa Strains with Increased Mutation Frequency Due to Inactivation of the DNA Oxidative Repair System Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2483 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Rodriguez-Martinez, L. Poirel, and P. Nordmann Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1766 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miller, C. J. Dunsmore, C. W. G. Fishwick, and I. Chopra Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1737 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ruiz, L. Mensa, M. J. Pons, J. Vila, and J. Gascon Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability J. Antimicrob. Chemother., May 1, 2008; 61(5): 1016 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ellington, D. M. Livermore, T. L. Pitt, L. M. C. Hall, and N. Woodford Mutators among CTX-M {beta}-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance J. Antimicrob. Chemother., October 1, 2006; 58(4): 848 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. C. Hall and S. K. Henderson-Begg Hypermutable bacteria isolated from humans - a critical analysis. Microbiology, September 1, 2006; 152(Pt 9): 2505 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Galan, M. Tato, M.-R. Baquero, C. Turrientes, F. Baquero, and J.-L. Martinez Fosfomycin and Rifampin Disk Diffusion Tests for Detection of Escherichia coli Mutator Strains J. Clin. Microbiol., September 1, 2004; 42(9): 4310 - 4312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Baquero, A. I. Nilsson, M. del Carmen Turrientes, D. Sandvang, J. C. Galan, J. L. Martinez, N. Frimodt-Moller, F. Baquero, and D. I. Andersson Polymorphic Mutation Frequencies in Escherichia coli: Emergence of Weak Mutators in Clinical Isolates J. Bacteriol., August 15, 2004; 186(16): 5538 - 5542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Smania, I. Segura, R. J. Pezza, C. Becerra, I. Albesa, and C. E. Argarana Emergence of phenotypic variants upon mismatch repair disruption in Pseudomonas aeruginosa Microbiology, May 1, 2004; 150(5): 1327 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miller, A. J. O'Neill, and I. Chopra Escherichia coli Mutators Present an Enhanced Risk for Emergence of Antibiotic Resistance during Urinary Tract Infections Antimicrob. Agents Chemother., January 1, 2004; 48(1): 23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, M.-R. Baquero, J. M. Sanchez-Romero, M.-C. Negri, J.-C. Galan, R. del Campo, J. C. Perez-Diaz, and F. Baquero Frequency of Mutation to Rifampin Resistance in Streptococcus pneumoniae Clinical Strains: hexA and hexB Polymorphisms Do Not Account for Hypermutation Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1464 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, I. Chopra, G. Bierbaum, A. Reipert, and F. Schaaff Lack of Evidence for Involvement of Hypermutability in Emergence of Vancomycin-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1484 - 1485. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bostock, K. Miller, A. J. O'Neill, and I. Chopra Zeocin resistance suppresses mutation in hypermutable Escherichia coli Microbiology, April 1, 2003; 149(4): 815 - 816. [Full Text] [PDF]
|
|
|
|
|
|
B. Oliva, K. Miller, N. Caggiano, A. J. O'Neill, G. D. Cuny, M. Z. Hoemann, J. R. Hauske, and I. Chopra Biological Properties of Novel Antistaphylococcal Quinoline-Indole Agents Antimicrob. Agents Chemother., February 1, 2003; 47(2): 458 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, J. M. Bostock, A. Morais Moita, and I. Chopra Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid J. Antimicrob. Chemother., December 1, 2002; 50(6): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill and I. Chopra Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low J. Antimicrob. Chemother., August 1, 2002; 50(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|